ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Joel D. Leverson et al.|Nature Medicine|2013Cited by 3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Matthew S. Davids et al.|New England Journal of Medicine|2015Cited by 1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Thomas J. Kipps, Bruce D. Cheson et al.|Blood|2018Cited by 1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElı́as Campo, Ari Melnick, Andrew D. Zelenetz et al.|Blood|2022Cited by 1.5k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907